New drugs: Ciclesonide, certolizumab pegol, and bendamustine hydrochloride.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of Science, Philadelphia, PA, USA.
D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D000069461:Bendamustine Hydrochloride; D000068582:Certolizumab Pegol; D003424:Crohn Disease / Q000188:drug therapy; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects; D011282:Pregnenediones / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy
D018926:Anti-Allergic Agents; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D007140:Immunoglobulin Fab Fragments; D009588:Nitrogen Mustard Compounds; D011282:Pregnenediones; D011092:Polyethylene Glycols; D000069461:Bendamustine Hydrochloride; C120481:ciclesonide; D000068582:Certolizumab Pegol